| Budget Amount *help |
¥2,300,000 (Direct Cost: ¥2,300,000)
Fiscal Year 2018: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 2017: ¥1,200,000 (Direct Cost: ¥1,200,000)
|
|---|
| Outline of Annual Research Achievements |
Recently blockade of a key negative regulator (PD-1) of immune system using antibody has led to a paradigm shift in the field of cancer drug discovery, owing to its durable effect against a wide variety of cancers and is termed as PD-1 blockade cancer immunotherapy. However, a substantial number of patients do not respond to this therapy. Thus, combination therapy to improve PD-1 blockade efficacy must be developed. To overcome the low response rate of PD-1 blockade therapy, various combinations have been used. But, many clinical trial reports have not shown encouraging results. We recently demonstrated that activation of PGC-1α, a key regulator of mitochondrial biogenesis, /peroxisome proliferator-activated receptors (PPARs) by bezafibrate improves the efficacy of PD-1 blockade. However, the mechanism of anti-tumor immunity development by activation of the PPAR pathway remains unknown. In this study, we investigated the effect of bezafibrate on phenotype of effector T cells and its mitochondrial activities followed by investigation of the molecular mechanism of how bezafibrate modulates the differentiation of CTLs and enhances T cell-based anti-tumor immunity. We found that bezafibrate upregulates fatty acid oxidation and inhibits the apoptosis of effector T cells. This effect of bezafibrate on the effector phase resulted in an increased number of effector T cells and augmentation of tumoricidal effect by PD-1 blockade. Therefore, PPAR signal activation in T cells may be a promising strategy for PD-1 blockade combination therapy.
|
